Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anastrozole |
Synonyms | |
Therapy Description |
Arimidex (anastrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (PMID: 29719441). Arimidex (anastrozole) is FDA approved for postmenopausal women with hormone receptor-positive early breast cancer or advanced patients who have failed tamoxifen therapy (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anastrozole | Arimidex | Anastrozol | Aromatase Inhibitor 3 | Arimidex (anastrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (PMID: 29719441). Arimidex (anastrozole) is FDA approved for postmenopausal women with hormone receptor-positive early breast cancer or advanced patients who have failed tamoxifen therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
No data available in table |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01272037 | Phase III | Anastrozole Letrozole Tamoxifen Exemestane | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Active, not recruiting | USA | IRL | FRA | ESP | CAN | 5 |
NCT01674140 | Phase III | Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3) | Active, not recruiting | USA | 1 |
NCT01723774 | Phase II | Palbociclib Anastrozole Goserelin | PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01824836 | Phase 0 | Anastrozole | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | Active, not recruiting | USA | 0 |
NCT01953588 | Phase III | Anastrozole Fulvestrant | Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery | Active, not recruiting | USA | 1 |
NCT02918084 | Phase III | Exemestane Anastrozole Letrozole | CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT) | Active, not recruiting | ITA | 0 |
NCT02947685 | Phase III | Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Palbociclib Trastuzumab | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) | Active, not recruiting | USA | NZL | ITA | FRA | ESP | DEU | AUS | 1 |
NCT03820830 | Phase III | Anastrozole Exemestane Anastrozole + Palbociclib Letrozole Letrozole + Palbociclib Exemestane + Palbociclib | Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR) | Active, not recruiting | ITA | HUN | FRA | ESP | CHE | AUT | 0 |
NCT04272801 | Phase II | Anastrozole Letrozole Tamoxifen Exemestane | Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER) | Active, not recruiting | USA | 0 |
NCT06001762 | Phase II | Tamoxifen Exemestane Abemaciclib Anastrozole Letrozole | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | Active, not recruiting | USA | 0 |
NCT00570323 | Phase II | Anastrozole + Fulvestrant Anastrozole | Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer | Completed | USA | 0 |
NCT00921115 | Phase II | Anastrozole Fulvestrant | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | Completed | USA | 0 |
NCT01160211 | Phase III | Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Completed | USA | TUR | POL | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DEU | BRA | BGR | BEL | AUS | ARG | 12 |
NCT01197170 | Phase I | Erlotinib Everolimus Sorafenib Anastrozole Bevacizumab | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | Completed | USA | 0 |
NCT01216176 | Phase Ib/II | Anastrozole Saracatinib | A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | Completed | USA | 0 |
NCT01491737 | Phase II | Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN) | Completed | USA | TUR | ITA | GBR | FRA | ESP | BRA | 1 |
NCT02040857 | Phase II | Exemestane Palbociclib Tamoxifen Letrozole Anastrozole | A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | Completed | USA | 0 |
NCT02095184 | Phase 0 | Anastrozole Letrozole | GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | Completed | USA | 0 |
NCT02188745 | Phase II | Exemestane Estradiol Anastrozole Letrozole | ER Reactivation Therapy for Breast Cancer (POLLY) | Completed | USA | 0 |
NCT02206984 | Phase I | Tamoxifen Anastrozole Fulvestrant | Endocrine Response in Women With Invasive Lobular Breast Cancer | Completed | USA | 0 |
NCT02441946 | Phase II | Abemaciclib Loperamide Anastrozole | A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer | Completed | USA | NLD | ITA | ESP | DEU | CAN | BEL | AUT | 2 |
NCT02753686 | Phase I | Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane | Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) | Completed | CAN | 0 |
NCT03219476 | Phase II | Anastrozole Letrozole Tamoxifen Exemestane | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | Completed | USA | 0 |
NCT03555877 | Phase II | Anastrozole Fulvestrant Fulvestrant + Ribociclib Letrozole Exemestane + Ribociclib Letrozole + Ribociclib Anastrozole + Ribociclib Exemestane | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA) | Completed | DEU | 0 |
NCT03778931 | Phase III | Letrozole Exemestane Elacestrant Fulvestrant Anastrozole | Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | Completed | USA | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CAN | BEL | AUT | AUS | ARG | 2 |
NCT05549505 | Phase II | Anastrozole Vepdegestrant | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | Completed | USA | ESP | DEU | 1 |
NCT06223698 | Phase III | Letrozole Anastrozole Exemestane Tamoxifen | Optimizing Extended Adjuvant Endocrine Therapy in Patients with Breast Cancer (SWE-Switch) | Not yet recruiting | SWE | 0 |
NCT02476786 | Phase II | Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | Recruiting | USA | 0 |
NCT04113863 | Phase II | Anastrozole Anastrozole + Tretinoin | Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (ATRA) | Recruiting | ITA | 0 |
NCT04134598 | Phase III | Tamoxifen Letrozole Anastrozole Exemestane | ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged >=70 Years Early Stage Breast Cancer (EUROPA) | Recruiting | ITA | 0 |
NCT04852887 | Phase III | Anastrozole Letrozole Tamoxifen Exemestane | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA) | Recruiting | USA | CAN | 2 |
NCT04886531 | Phase II | Anastrozole + Neratinib + Trastuzumab Letrozole + Neratinib + Trastuzumab Neratinib Anastrozole + Neratinib Letrozole + Neratinib Letrozole Anastrozole Anastrozole + Trastuzumab | Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | Recruiting | USA | 0 |
NCT04961996 | Phase III | Exemestane Giredestrant Letrozole Anastrozole | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | Recruiting | USA | TUR | SWE | SVN | SVK | ROU | POL | NLD | LVA | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 25 |
NCT05150652 | Phase II | Exemestane Tamoxifen Letrozole Anastrozole | Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer | Recruiting | USA | 0 |
NCT05472792 | Phase II | Toremifene Exemestane Tamoxifen Letrozole Anastrozole Fulvestrant | Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy (CAMERAN) | Recruiting | USA | 0 |
NCT05501704 | Phase II | Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Anastrozole + Degarelix Anastrozole + Degarelix Anastrozole | ETHAN - ET for Male BC | Recruiting | USA | 0 |
NCT05512364 | Phase III | Letrozole Anastrozole Exemestane Elacestrant Tamoxifen | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA) | Recruiting | ITA | IRL | FRA | DEU | BEL | 0 |
NCT05514054 | Phase III | Letrozole Anastrozole Exemestane Tamoxifen LY3484356 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) | Recruiting | USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05774951 | Phase III | Tamoxifen Exemestane Anastrozole Letrozole Camizestrant | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 18 |
NCT05837455 | Phase II | Anastrozole | NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT05952557 | Phase III | Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Exemestane Abemaciclib + Camizestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Exemestane Anastrozole Letrozole | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) | Recruiting | USA | TUR | ROU | POL | NZL | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 19 |
NCT06016738 | Phase III | Fulvestrant Letrozole Anastrozole Palazestrant Exemestane | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01) | Recruiting | USA | ROU | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 8 |
NCT06044623 | Phase III | Exemestane Abemaciclib Palbociclib Ribociclib Letrozole Anastrozole Fulvestrant | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT) | Recruiting | SWE | NOR | ITA | GRC | FIN | ESP | 0 |
NCT06072781 | Phase III | Paclitaxel Pegylated liposomal doxorubicin Defactinib + RO5126766 Topotecan Anastrozole Letrozole | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301) | Recruiting | USA | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT06179303 | Phase II | Tamoxifen Exemestane Abemaciclib Fulvestrant Letrozole Anastrozole | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | Recruiting | USA | 0 |
NCT06380751 | Phase III | Ribociclib Fulvestrant Camizestrant + Saruparib Anastrozole Camizestrant + Ribociclib Letrozole Camizestrant + Palbociclib Abemaciclib + Camizestrant Exemestane Abemaciclib Palbociclib | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 11 |
NCT06492616 | Phase III | Exemestane Elacestrant Tamoxifen Letrozole Anastrozole | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | Recruiting | USA | ROU | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUT | AUS | 5 |
NCT06671912 | Phase III | Exemestane Tamoxifen Letrozole Anastrozole | Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (LoTam) | Recruiting | USA | 1 |
NCT02269670 | Phase II | Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole | Phase II Study of Everolimus Beyond Progression | Terminated | USA | 0 |
NCT02689921 | Phase II | Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT) | Unknown status | USA | 0 |
NCT03238703 | FDA approved | Tamoxifen Exemestane Toremifene Anastrozole Letrozole | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | Withdrawn | USA | 0 |
NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: